Literature DB >> 15240373

Leaky catecholamine stores: undue waste or a stress response coping mechanism?

Graeme Eisenhofer1, Irwin J Kopin, David S Goldstein.   

Abstract

Turnover of catecholamines, representing the constant loss and replenishment of neurotransmitter by synthesis, is usually considered to be driven exclusively by catecholamine release. This is incorrect. An important contribution of intraneuronal metabolism of norepinephrine to turnover, and dependence of this on leakage of norepinephrine from vesicular stores, was originally proposed by Kopin in 1964. Several years later, Maas and colleagues concluded that at least 75% of norepinephrine turnover is due to intraneuronal metabolism without prior release at sympathetic nerve endings. More recently it was shown in the resting human heart that about 12% of norepinephrine turnover is due to extraneuronal uptake and metabolism or loss of the transmitter to the circulation, 15% is due to intraneuronal metabolism after reuptake, and 73% is due to intraneuronal metabolism of norepinephrine leaking from storage vesicles. Thus, contrary to usual depictions, vesicular stores of catecholamines do not exist in a static state simply waiting for exocytotic release. Rather, these stores exist in a highly dynamic equilibrium with the surrounding cytoplasm, with passive outward leakage of amines counterbalanced by inward active transport under the control of vesicular monoamine transporters. The large contribution of leakage to catecholamine turnover may seem inconsistent with cellular economy. In fact, this contribution provides an important mechanism for "gearing down" the requirement for increases in catecholamine synthesis to match increases in catecholamine release, and thereby provides sympathetic nerves with a capacity for a more extended range of sustainable release rates in response to stress than would otherwise be possible.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240373     DOI: 10.1196/annals.1296.027

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  23 in total

Review 1.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  David S Goldstein
Journal:  Cell Mol Neurobiol       Date:  2012-07       Impact factor: 5.046

Review 2.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

Review 3.  Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

Review 4.  Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases.

Authors:  D S Goldstein
Journal:  Endocr Regul       Date:  2011-04

5.  Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite.

Authors:  John M Bruning; Yan Wang; Francesca Oltrabella; Boxue Tian; Svetlana A Kholodar; Harrison Liu; Paulomi Bhattacharya; Su Guo; James M Holton; Robert J Fletterick; Matthew P Jacobson; Pamela M England
Journal:  Cell Chem Biol       Date:  2019-03-07       Impact factor: 8.116

6.  Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study.

Authors:  L V Darbinyan; L E Hambardzumyan; K V Simonyan; V A Chavushyan; L P Manukyan; S A Badalyan; N Khalaji; V H Sarkisian
Journal:  Metab Brain Dis       Date:  2017-07-10       Impact factor: 3.584

7.  Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats.

Authors:  Megan M Kangiser; Linda P Dwoskin; Guangrong Zheng; Peter A Crooks; Dustin J Stairs
Journal:  Behav Pharmacol       Date:  2018-02       Impact factor: 2.293

8.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

Review 9.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

Review 10.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.